The BAG2 Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population of human liver adenocarcinoma SK-HEP-1 cells engineered to disrupt the BAG2 gene. This polyclonal knockout model provides a heterogeneous mixture of gene-edited cells, each bearing a targeted disruption within BAG2, enabling pooled functional analysis of BAG2 loss-of-function phenotypes. The broad allelic diversity offers a robust system for observing collective cellular responses without the constraints of clonal selection.
The SK-HEP-1 cell line was initially derived from the ascitic fluid of a patient with liver adenocarcinoma and is characterized as a hepatocellular carcinoma model with endothelial-like features. These epithelial cells retain key hepatic cancer traits, including aggressive proliferation and tumorigenicity. Their unique dual endothelial and epithelial properties make them a valuable tool for investigating liver cancer biology and tumor microenvironment interactions.
BAG2 (BCL2-associated athanogene 2) encodes a co-chaperone that directly binds to the heat shock cognate 71 kDa protein HSC70 (HSPA8), modulating protein folding and degradation. Through this interaction, BAG2 suppresses the E3 ubiquitin ligase activity of parkin (PRKN), thereby inhibiting mitophagy and preserving mitochondrial integrity. BAG2 is regulated by cellular stress signals, including heat shock and oxidative stress, acting downstream of HSF1 and ERK1/2. It also interacts with BAG3, BCL2, and CHIP/STUB1, forming complexes that govern apoptosis and proteostasis. Notably, BAG2 promotes the proteasome-mediated degradation of tau/MAPT, linking it to proteinopathies. BAG2 thus integrates stress signals to control protein homeostasis and cell fate.
In hepatocellular carcinoma, BAG2 upregulation has been associated with enhanced chemoresistance and impaired apoptosis. Disruption of BAG2 in SK-HEP-1 cells offers a physiologically relevant model to dissect BAG2??s contributions to liver cancer cell survival and drug response. The polyclonal knockout population enables examination of heterogeneous signaling outcomes, particularly in pathways regulating autophagy, mitophagy, and proteostasis, without clonal bias. This model is well-suited for investigating how BAG2 loss alters mitochondrial quality control, tau processing, and the ubiquitin-proteasome system in hepatic cancer cells.
Researchers can employ this BAG2 knockout polyclonal cell pool to investigate autophagy flux via LC3-II immunoblotting and immunofluorescence for LC3 puncta formation. Co-immunoprecipitation studies can assess BAG2??s impact on HSC70 and parkin interactions. Drug sensitivity assays with sorafenib, together with Annexin V flow cytometry for apoptosis detection, enable chemoresistance profiling. Additional metabolic assays, such as ATP production measurement, can probe mitochondrial function. This BAG2-disrupted model serves as a versatile tool for studying protein quality control and mitophagy in liver cancer and neurodegenerative disease contexts. For technical inquiries, please contact Ascent Research.
